$DFCO
DALRADA FINANCIAL CORP Stock $dfco

$dfco Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000168316824003323 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue		$10.31M	$9.475M
YoY Change		8.77%	69.43%
Cost Of Revenue		$5.594M	$6.613M
YoY Change		-15.4%	272.83%
Gross Profit		$4.711M	$2.862M
YoY Change		64.62%	-25.05%
Gross Profit Margin		45.72%	30.21%
Selling, General & Admin		$7.001M	$6.501M
YoY Change		7.69%	3.3%
% of Gross Profit		148.6%	227.16%
Research & Development			$0.00
YoY Change
% of Gross Profit			0.0%
Depreciation & Amortization		$170.7K	$94.33K
YoY Change		80.95%	50.57%
% of Gross Profit		3.62%	3.3%
Operating Expenses		$7.001M	$6.501M
YoY Change		7.69%	0.67%
Operating Profit		-$2.290M	-$3.639M
YoY Change		-37.08%	37.87%
Interest Expense		$347.3K	$314.3K
YoY Change		10.5%	-189.94%
% of Operating Profit
Other Income/Expense, Net		-$617.9K	-$406.6K
YoY Change		51.97%	10141.26%
Pretax Income		-$2.908M	-$4.046M
YoY Change		-28.13%	35.17%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings		-$2.883M	-$4.026M
YoY Change		-28.39%	17.6%
Net Earnings / Revenue		-27.97%	-42.49%
Basic Earnings Per Share		-$0.03	-$0.05
Diluted Earnings Per Share		-$0.03	-$0.05
COMMON SHARES
Basic Shares Outstanding	97.05M shares	90.39M shares	85.66M shares
Diluted Shares Outstanding		92.93M shares	85.73M shares

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$533.6K	$1.289M
YoY Change	-58.6%	135.51%
Cash & Equivalents	$533.6K	$1.289M
Short-Term Investments
Other Short-Term Assets	$582.9K	$337.8K
YoY Change	72.54%	109.01%
Inventory	$2.753M	$2.321M
Prepaid Expenses
Receivables	$9.841M	$8.218M
Other Receivables	$1.263M	$534.8K
Total Short-Term Assets	$15.88M	$12.83M
YoY Change	23.81%	31.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.426M	$1.404M
YoY Change	1.56%	-34.38%
Goodwill	$3.803M	$4.253M
YoY Change	-10.59%
Intangibles	$3.561M	$3.920M
YoY Change	-9.18%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$14.29M	$15.90M
YoY Change	-10.16%	323.84%
TOTAL ASSETS
Total Short-Term Assets	$15.88M	$12.83M
Total Long-Term Assets	$14.29M	$15.90M
Total Assets	$30.17M	$28.73M
YoY Change	5.01%	112.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.692M	$4.598M
YoY Change	23.8%	344.89%
Accrued Expenses	$1.132M	$1.717M
YoY Change	-34.12%	-56.0%
Deferred Revenue		$1.973M
YoY Change
Short-Term Debt	$0.00	$16.73M
YoY Change	-100.0%	148.34%
Long-Term Debt Due	$1.733M	$1.035M
YoY Change	67.42%
Total Short-Term Liabilities	$10.56M	$28.94M
YoY Change	-63.53%	113.22%
LONG-TERM LIABILITIES
Long-Term Debt	$2.919M	$13.73M
YoY Change	-78.74%	37.0%
Other Long-Term Liabilities	$7.872M	$8.767M
YoY Change	-10.21%	948.43%
Total Long-Term Liabilities	$10.79M	$22.49M
YoY Change	-52.03%	107.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.56M	$28.94M
Total Long-Term Liabilities	$10.79M	$22.49M
Total Liabilities	$21.35M	$51.44M
YoY Change	-58.5%	100.47%
SHAREHOLDERS EQUITY
Retained Earnings	-$154.8M	-$133.5M
YoY Change	15.99%
Common Stock	$481.3K	$431.2K
YoY Change	11.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.760M	-$23.54M
YoY Change
Total Liabilities & Shareholders Equity	$30.17M	$28.73M
YoY Change	5.01%	112.62%

Cashflow Statement

Concept	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$2.883M	-$4.026M
YoY Change	-28.39%	17.6%
Depreciation, Depletion And Amortization	$170.7K	$94.33K
YoY Change	80.95%	50.57%
Cash From Operating Activities	-$2.184M	-$5.163M
YoY Change	-57.7%	81.97%
INVESTING ACTIVITIES
Capital Expenditures	-$26.58K	-$32.87K
YoY Change	-19.14%	-89.39%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$9.110K
YoY Change	-100.0%
Cash From Investing Activities	$26.58K	$41.98K
YoY Change	-36.68%	-113.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.139M	4.873M
YoY Change	-56.11%	38.5%
NET CHANGE
Cash From Operating Activities	-2.184M	-5.163M
Cash From Investing Activities	26.58K	41.98K
Cash From Financing Activities	2.139M	4.873M
Net Change In Cash	-18.67K	-247.9K
YoY Change	-92.47%	-166.73%
FREE CASH FLOW
Cash From Operating Activities	-$2.184M	-$5.163M
Capital Expenditures	-$26.58K	-$32.87K
Free Cash Flow	-$2.158M	-$5.130M
YoY Change	-57.94%	102.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000725394
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	DFCO	Common Stock Issued For Conversion Of Convertibles Notes Accrued Interest And Premium CommonStockIssuedForConversionOfConvertiblesNotesAccruedInterestAndPremium		usd
CY2023Q3	DFCO	Conversion Of Related Party Notes Into Preferred Stock Value ConversionOfRelatedPartyNotesIntoPreferredStockValue		usd
CY2024Q1	DFCO	Common Stock Issued Pursuant To Private Placement CommonStockIssuedPursuantToPrivatePlacement		usd
	us-gaap	Net Income Loss NetIncomeLoss	-13105260	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-154834269	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5660542	usd
	DFCO	Finite Lived Intangible Assets Additions FiniteLivedIntangibleAssetsAdditions		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-12641
	dei	Entity Registrant Name EntityRegistrantName	DALRADA FINANCIAL CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	WY
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	38-3713274
	dei	Entity Address Address Line1 EntityAddressAddressLine1	600 La Terraza Blvd.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Escondido
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92025
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	283-1253
	dei	Security12b Title Security12bTitle	Common Stock, $0.005 par value per share
	dei	Trading Symbol TradingSymbol	DFCO
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	97050443	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	533595	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	812806	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9841425	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4453104	usd
CY2024Q1	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	909279	usd
CY2023Q2	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	752348	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1262756	usd
CY2023Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	376604	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	2753208	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2078692	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	582894	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1343491	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	15883157	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	9817045	usd
CY2024Q1	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	20756	usd
CY2023Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	41722	usd
CY2024Q1	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1146064	usd
CY2023Q2	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1173893	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1425828	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1476082	usd
CY2024Q1	us-gaap	Goodwill Goodwill	3803147	usd
CY2023Q2	us-gaap	Goodwill Goodwill	3803147	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3560524	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3858086	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2504035	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2771854	usd
CY2024Q1	DFCO	Operating Lease Right Of Use Asset Related Party OperatingLeaseRightOfUseAssetRelatedParty	1825640	usd
CY2023Q2	DFCO	Operating Lease Right Of Use Asset Related Party OperatingLeaseRightOfUseAssetRelatedParty	2227286	usd
CY2024Q1	us-gaap	Assets Assets	30169151	usd
CY2023Q2	us-gaap	Assets Assets	25169115	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5691861	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5178897	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1131541	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1084008	usd
CY2024Q1	DFCO	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	254295	usd
CY2023Q2	DFCO	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	547949	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	471423	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1337259	usd
CY2024Q1	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1733071	usd
CY2023Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	439562	usd
CY2024Q1	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	0	usd
CY2023Q2	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	251605	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	730602	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	660394	usd
CY2024Q1	DFCO	Operating Lease Liability Current Related Party OperatingLeaseLiabilityCurrentRelatedParty	542369	usd
CY2023Q2	DFCO	Operating Lease Liability Current Related Party OperatingLeaseLiabilityCurrentRelatedParty	519791	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10555162	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10019465	usd
CY2024Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	usd
CY2023Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	48888	usd
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	2281129	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	1011395	usd
CY2024Q1	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	637688	usd
CY2023Q2	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	1648478	usd
CY2024Q1	DFCO	Contingent Consideration ContingentConsideration	4691794	usd
CY2023Q2	DFCO	Contingent Consideration ContingentConsideration	4285389	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1849125	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2160834	usd
CY2024Q1	DFCO	Operating Lease Liability Noncurrent Related Party OperatingLeaseLiabilityNoncurrentRelatedParty	1330873	usd
CY2023Q2	DFCO	Operating Lease Liability Noncurrent Related Party OperatingLeaseLiabilityNoncurrentRelatedParty	1741830	usd
CY2024Q1	us-gaap	Liabilities Liabilities	21345771	usd
CY2023Q2	us-gaap	Liabilities Liabilities	20916279	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96258774	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96258774	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	88699139	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	88699139	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	481294	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	443478	usd
CY2024Q1	DFCO	Common Stock To Be Issued CommonStockToBeIssued	128925	usd
CY2023Q2	DFCO	Common Stock To Be Issued CommonStockToBeIssued	192925	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	162968758	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	145251822	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-154834269	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141729009	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14707	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50848	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	8760226	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4109019	usd
CY2024Q1	us-gaap	Minority Interest MinorityInterest	63154	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	143817	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8823380	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4252836	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30169151	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25169115	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9780962	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9290805	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19761828	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18066932	usd
CY2024Q1	DFCO	Revenues Related Party RevenuesRelatedParty	524829	usd
CY2023Q1	DFCO	Revenues Related Party RevenuesRelatedParty	183888	usd
	DFCO	Revenues Related Party RevenuesRelatedParty	1639805	usd
	DFCO	Revenues Related Party RevenuesRelatedParty	918648	usd
CY2024Q1	us-gaap	Revenues Revenues	10305791	usd
CY2023Q1	us-gaap	Revenues Revenues	9474693	usd
	us-gaap	Revenues Revenues	21401633	usd
	us-gaap	Revenues Revenues	18985580	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	5594338	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	6612680	usd
	us-gaap	Cost Of Revenue CostOfRevenue	13717562	usd
	us-gaap	Cost Of Revenue CostOfRevenue	11924140	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	4711453	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	2862013	usd
	us-gaap	Gross Profit GrossProfit	7684071	usd
	us-gaap	Gross Profit GrossProfit	7061440	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7001185	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6501233	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19271273	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18438927	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	7001185	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	6501233	usd
	us-gaap	Operating Expenses OperatingExpenses	19271273	usd
	us-gaap	Operating Expenses OperatingExpenses	18438927	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2289732	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3639220	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11587202	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11377487	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	347317	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	314319	usd
	us-gaap	Interest Expense InterestExpense	674470	usd
	us-gaap	Interest Expense InterestExpense	2207049	usd
CY2024Q1	us-gaap	Interest Income Operating InterestIncomeOperating	26995	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	18830	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	67122	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	60725	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-196604	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-72933	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-885303	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-179555	usd
CY2024Q1	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	0	usd
CY2023Q1	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	0	usd
	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	0	usd
	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	2090978	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-100949	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-38156	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-106070	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-85751	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-617875	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-406578	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1598721	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-320652	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2907607	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4045798	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13185923	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11698139	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-2907607	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4045798	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-13185923	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-11698139	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	19373	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-137	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	65555	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	29496	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2888234	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4045935	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13120368	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11668643	usd
CY2024Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-24787	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-20234	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-80663	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	358232	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2882820	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4025564	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13105260	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12056371	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	92934331	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85728770	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90658476	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82356784	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	92934331	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85728770	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90658476	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82356784	shares
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14953182	usd
CY2022Q3	DFCO	Common Stock Issued For Conversion Of Convertible Notes Accrued Interest And Premium CommonStockIssuedForConversionOfConvertibleNotesAccruedInterestAndPremium	1111397	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	172350	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	467517	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3170176	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	63762	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-16308332	usd
CY2022Q4	DFCO	Common Stock Issued For Conversion Of Convertible Notes Accrued Interest And Premium CommonStockIssuedForConversionOfConvertibleNotesAccruedInterestAndPremium	336091	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	75459	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	901721	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-4482165	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-34129	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-19511355	usd
CY2023Q1	DFCO	Common Stock Issued Pursuant To Acquisitions Value CommonStockIssuedPursuantToAcquisitionsValue	36667	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	815454	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-4045798	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-137	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-22705169	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4252836	usd
CY2023Q3	DFCO	Common Stock Issued Pursuant To Acquisitions Value CommonStockIssuedPursuantToAcquisitionsValue	269	usd
CY2023Q3	DFCO	Common Stock Issued Pursuant To Debt Agreement CommonStockIssuedPursuantToDebtAgreement	60000	usd
CY2023Q3	DFCO	Warrants Issued Pursuant To Acquisitions WarrantsIssuedPursuantToAcquisitions	5478	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1109642	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-4838136	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	85208	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	675297	usd
CY2023Q4	DFCO	Common Stock Issued Pursuant To Acquisitions Value CommonStockIssuedPursuantToAcquisitionsValue	70667	usd
CY2023Q4	DFCO	Common Stock Issued Pursuant To Debt Agreement CommonStockIssuedPursuantToDebtAgreement	173000	usd
CY2023Q4	DFCO	Warrants Issued Pursuant To Acquisitions WarrantsIssuedPursuantToAcquisitions	5748	usd
CY2023Q4	DFCO	Common Stock To Be Issued For Private Placement CommonStockToBeIssuedForPrivatePlacement	604000	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1018827	usd
CY2023Q4	us-gaap	Profit Loss ProfitLoss	-5440180	usd
CY2023Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-39026	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2931667	usd
CY2024Q1	DFCO	Conversion Of Related Party Notes To Preferred Stock Value ConversionOfRelatedPartyNotesToPreferredStockValue	13318943	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-428924	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-752256	usd
CY2024Q1	DFCO	Common Stock Issued Pursuant To Consulting Agreement CommonStockIssuedPursuantToConsultingAgreement	241200	usd
CY2024Q1	DFCO	Warrants Issued Pursuant To Acquisitions WarrantsIssuedPursuantToAcquisitions	5748	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1077390	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-2907607	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	19373	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8823380	usd
	us-gaap	Profit Loss ProfitLoss	-13185923	usd
	us-gaap	Profit Loss ProfitLoss	-11698139	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	620676	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	530177	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3205859	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2184692	usd
	DFCO	Stock Consideration Issued To Vendor StockConsiderationIssuedToVendor	474200	usd
	DFCO	Stock Consideration Issued To Vendor StockConsiderationIssuedToVendor	0	usd
	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	477072	usd
	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	181009	usd
	DFCO	Bad Debt Expense BadDebtExpense	527741	usd
	DFCO	Bad Debt Expense BadDebtExpense	640484	usd
	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	-0	usd
	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	2090978	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6077304	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2787677	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	859709	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	218817	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	653070	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	696695	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-780979	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-128542	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-49013	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-26889	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	544966	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2241421	usd
	DFCO	Increase Decrease In Longterm Payables IncreaseDecreaseInLongtermPayables	-48888	usd
	DFCO	Increase Decrease In Longterm Payables IncreaseDecreaseInLongtermPayables	-47329	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	9052657	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	522620	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	278429	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-217742	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	0	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	35242	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-847240	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1191593	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5660542	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10074709	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	272783	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	511515	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	446923	usd
	DFCO	Acquisition Of Business Net Of Cash AcquisitionOfBusinessNetOfCash	0	usd
	DFCO	Acquisition Of Business Net Of Cash AcquisitionOfBusinessNetOfCash	80087	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-272783	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-878351	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	2913980	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	11845764	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	2565040	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	346910	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	604000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5654096	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11440418	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-279229	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	487358	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29496	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	812806	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	772062	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	533595	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1288916	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	356231	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	DFCO	Conversion Of Related Party Notes And Interest Into Preferred Stock ConversionOfRelatedPartyNotesAndInterestIntoPreferredStock	11324793	usd
	DFCO	Conversion Of Related Party Notes And Interest Into Preferred Stock ConversionOfRelatedPartyNotesAndInterestIntoPreferredStock	0	usd
	DFCO	Conversion Of Accounts Payablerelated Parties To Note Payablerelated Parties ConversionOfAccountsPayablerelatedPartiesToNotePayablerelatedParties	1993990	usd
	DFCO	Conversion Of Accounts Payablerelated Parties To Note Payablerelated Parties ConversionOfAccountsPayablerelatedPartiesToNotePayablerelatedParties	0	usd
	DFCO	Common Stock Issued Pursuant To Business Combination CommonStockIssuedPursuantToBusinessCombination	70936	usd
	DFCO	Common Stock Issued Pursuant To Business Combination CommonStockIssuedPursuantToBusinessCombination	0	usd
	DFCO	Conversion Of Convertible Note Payable Accrued Interest And Premium Into Common Stock ConversionOfConvertibleNotePayableAccruedInterestAndPremiumIntoCommonStock	0	usd
	DFCO	Conversion Of Convertible Note Payable Accrued Interest And Premium Into Common Stock ConversionOfConvertibleNotePayableAccruedInterestAndPremiumIntoCommonStock	2327489	usd
	DFCO	Warrants Issued Pursuant To Acquisitions WarrantsIssuedPursuantToAcquisitions	16974	usd
	DFCO	Warrants Issued Pursuant To Acquisitions WarrantsIssuedPursuantToAcquisitions	0	usd
	DFCO	Operating Liabilities Satisfied By Related Parties OperatingLiabilitiesSatisfiedByRelatedParties	1993990	usd
	DFCO	Operating Liabilities Satisfied By Related Parties OperatingLiabilitiesSatisfiedByRelatedParties	0	usd
	DFCO	Increase In Right Of Use Asset And Liability IncreaseInRightOfUseAssetAndLiability	-39719	usd
	DFCO	Increase In Right Of Use Asset And Liability IncreaseInRightOfUseAssetAndLiability	1447488	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80E_eus-gaap--NatureOfOperations_zuHmKIbQqFEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify"><span style="font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify"><span style="font-size: 10pt"><b><span id="xdx_82E_zb0o36flhEh2">Organization and Nature of Operations</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Moving the world forward takes bold resolve that turns ideas into actions and builds real-time solutions that positively impact people and the planet. Dalrada accelerates positive change for current and future generations by harnessing true potential and developing products and services that become transformative innovations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Financial Corporation, (“Dalrada” or the “Company”), was incorporated in September 1982 under the laws of the State of California. It was reincorporated in May 1983 under the laws of the State of Delaware and reincorporated again on May 5, 2020, under the laws of the state of Wyoming. Dalrada Financial Corporation trades under the symbol, OTCQB: DFCO.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada has five business divisions: <b>Genefic</b>, <b>Dalrada Climate Technology</b>, <b>Dalrada Precision Manufacturing</b>, <b>Dalrada Technologies </b>and <b>Dalrada Corporate</b>. Within each of these divisions, the Company drives transformative innovation while creating solutions that are sustainable, accessible, and affordable. Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate a new era of human behavior and interaction and ensure a bright future for the world around us.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Genefic (Formerly Dalrada Health)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Genefic delivers advanced health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness clinics, When the world needs advanced health care, Genefic delivers with ingenuity, accessibility, and affordability. This specialized division is committed to developing key health products, lifesaving medications and building comprehensive systems to increase capability, strive to keep people healthy with the goals of improving their quality of life and increasing their longevity– on a global level.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Genefic Specialty Pharmacy (“Genefic Pharmacy”)</b>- Genefic Pharmacy (formerly Watson Rx Solutions) is an Alabama-based pharmacy with more than 30 years of experience in the retail medical and pharmaceutical industries. Genefic Pharmacy specializes in providing expert care and managing disease states through comprehensive prescription management, education, nursing, and total health solutions. Genefic Pharmacy maintains pharmacy licenses in all 50 States as well as Washington D.C.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Boost Diagnostics</b>- Boost Diagnostics (formerly Empower Genomics and Genefic Diagnostics) is Dalrada’s wholly owned diagnostic laboratory subsidiary which processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Boost Diagnostics has built up and maintained the testing capacity to handle surges in COVID-19 testing demands. Boost Diagnostics also offers genetic testing capabilities including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Pala Diagnostics (“Pala”)</b>- Pala was a joint venture diagnostic laboratory entity which processed both molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Pala was no longer an operational entity as of June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Dalrada Career Institute (“DCI”) (aka International Health Group (“IHG”)) </b>- IHG provides highly trained nursing and medical assistants for hospitals and home health facilities since 2006. IHG Medical Assistant programs include Certified Nursing Assistant (“CNA") and Home Health Aide (“HHA”) training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility. DCI started its first RN, nursing class in February of 2024 and this first class will be completed in December 2024. It is the intent of DCI to double their class size when they begin their second class in 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Genefic Wellness Group (“Genefic Wellness”)</b>- Genefic Wellness (formerly Solas Corp.) manages and oversees wellness clinics throughout Southern California including the Sòlas Rejuvenation + Wellness clinics (“Sòlas”). Through advanced medical techniques and modern technology, Sòlas delivers a clinical experience that helps men and woman live their best life, whether it’s through simple cosmetic procedures, pain-reducing practices, or anti-aging therapies. Through its three locations, Sòlas prides itself on its dedicated service-focused, health-first approach. Its wellness & rejuvenation clinics deliver with a focus on regenerative therapies, IV and injection services, cosmetic enhancements amongst a myriad of additional health centric services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Dalrada Climate Technology (formerly Dalrada Energy Services)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Climate Technology (“DCT”) is a segment which incapsulates energy services and state-of-the-art technology within the climate sustainability space. DCT employs next-generation technology and services which enhances clean energy efforts while reducing the world’s carbon footprint. As a premier industrial heat pump manufacturer, Dalrada delivers innovation and efficiency, building solutions that reduce energy consumption and minimize carbon footprints, increase operational efficiencies, meet environmental, social, and governance (ESG) goals, and lower energy costs for clients. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Dalrada Technology Limited (“DTL”) - </b>DTL is a holding company for all United Kingdom and European based Dalrada Climate Technology entities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Likido Ltd. (“Likido”)</b> - Likido is an international engineering company developing advanced solutions for the harvesting and recycling of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling applications. With uses across industrial, commercial and residential sectors, Likido provides cost savings and minimized carbon emissions across global supply chains. Likido's technologies enable the effective recovery and recycling of process energy, mitigating against climate change and expected enhancement of quality of life through the provision of low-carbon heating and cooling systems. Likido’s products currently include the DCT One Heat Pumps (formerly Likido®ONE) and DCT Cryo Chiller.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the prior year, the U.S. Government selected DCT One Series high-performance, low-carbon heat pump for real-world testing in a prestigious clean energy program. The implementation of the DCT One Series testing is still in process. The expected positive results should not only increase market acceleration and adoption within the federal government acceptance of groundbreaking eco-friendly technology but should also accelerate adoption within the commercial building industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Dalrada Technology Spain L.T. (“DTS”)- </b>DTS was established as a Spanish subsidiary of DTL for the expansion of the manufacturing and sale of the DCT One Series and DCT Cryo Chiller throughout Europe.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Dalrada Energy Services (“DES”)</b>- DES provides end-to-end comprehensive energy service solutions in a robust commercial capacity. DES helps organizations meet ESG goals and standards while mitigating negative environmental impacts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Bothof Brothers Construction (“Bothof”)</b>- Bothof is a licensed general contractor which provides a wide range of development, construction and design capabilities and expertise throughout the United States. Through Bothof’s extensive experience in construction and contracting, the DES division can provide a myriad of additional services to its private and public works customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Dalrada Financial Corporation Morocco (“DFCM”)- </b>DFCM was established as a Moroccan subsidiary of Dalrada to conduct energy service solutions within the country of Morocco. Dalrada owns a <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DalradaFinancialCorporationMoroccoMember_zTWymoacLR4j">33</span>% equity interest in DFCM.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Dalrada Home Corporation (“Dalrada Home”)- </b>Dalrada Home Corporation was established in February of 2024. Dalrada Home’s cutting-edge sustainability solutions are designed specifically for residential purposes. Our home heat pumps help us lead the way in providing innovative climate technology products and services to residential customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Dalrada Precision Manufacturing</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Precision Manufacturing creates total manufacturing solutions that start with the design and development of high-quality machine parts and components, and end with an efficient global supply chain. This specialized business division can meet today’s high demands and solves industry challenges. Dalrada Precision Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with in-house research, design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Dalrada Precision Parts (“Precision”)</b> - Precision extends the client its engineering and operations team by helping devise unique manufacturing solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept and design to mass production and logistics.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Deposition Technologies (“DepTec”)</b> - DepTec designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">DepTec has built an impressive catalogue of precision OEM parts for PVD (Physical vapor deposition) systems and the Company’s refurbished systems which allows clients the option of purchasing the same model of system they’ve been using for decades –but with significant upgrades and improved efficiencies. Older systems can now operate more reliably with additional control and monitoring plus longer lifespans. DepTec also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD and EVOS -CVD, which deposits metals and non-metals for microchips used in almost every standard and specialized microdevices made today and in the future. These systems can produce a superior film layer utilized in rugged high-stress environment designs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Ignite I.T. (“Ignite”)</b> - Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that are specially formulated to lift hydrocarbon-based dirt and grease from virtually all surfaces with minimal effort. Ignite products are non-flammable, non-corrosive, non-toxic, butyl-free, water-based, and leave a light citrus scent. Ignite is developed for all surfaces suitable for water and meets or exceed the most stringent industry-testing specifications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Dalrada Technologies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Technologies has worked with some of the world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a host of robust digital services. This business division connects the world with integrated technology and innovative solutions, delivering advanced capabilities and error-free results. Dalrada Technologies creates digital products with expert computer information technology and software engineering services for a variety of technical industries and clients in both B2B and B2C environments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Prakat (“Prakat”)</b> - Prakat is an ISO 9001-certified company that provides end-to-end technology services across various industries, improving the value chain. The Company specializes in test engineering, accessibility engineering, product engineering, application modernization, billing and revenue management, CRM, and block chain. Prakat provides global customers with software and technology solutions specializing in Test Engineering, Accessibility Engineering, Product Engineering and Application Modernization.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Dalrada Corporate</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Corporate covers the activities which support the entire suite of Dalrada subsidiaries. Dalrada Corporate includes the areas of administration, finance, human resources, legal advice, information technology, and marketing. It also contains executive management and shareholder-related services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Going Concern</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unaudited interim consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the continued financial support from related parties, its ability to identify future investment opportunities, obtain the necessary debt or equity financing, and generate profitable operations. The Company had net losses of approximately $<span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_pp0p0_dixL_c20230701__20240331_z0bgWNbCffsc" title="Net loss::XDX::13105260"><span style="-sec-ix-hidden: xdx2ixbrl1312">13.1</span></span> million, accumulated deficit of $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_dixL_c20240331_zuLu3h1BlqLe" title="Accumulated deficit::XDX::154834269"><span style="-sec-ix-hidden: xdx2ixbrl1314">154.8</span></span> million and net cash used in operations of $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pp0p0_dixL_c20230701__20240331_zomcPwDLLfz6" title="Net cash used in operations::XDX::5660542"><span style="-sec-ix-hidden: xdx2ixbrl1316">5.7</span></span> million for the nine months ended March 31, 2024. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of twelve months from the issue date of this report. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zM1t0ycC6r21" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_86B_zY2A3wpGLyLg">Use of Estimates</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of these unaudited interim consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the revenue, valuation of inventory, valuation of acquired assets and liabilities, variables used in the computation of share-based compensation, litigation, contingent consideration, and evaluation of goodwill and intangible assets for impairment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_z5UKj6S52xKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-size: 10pt">(d)</span></td> <td style="text-align: justify"><span style="font-size: 10pt"><span id="xdx_86C_z387eILMQXd2">Concentrations of Credit Risk</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, as well as accounts receivable. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">When estimating its allowance for credit losses related to revenues from Covid Testing and pharmacy sales, the Company differentiates its receivables based on the following customer types: healthcare insurers, government payers, and cash payers. Additionally, the Company applies assumptions and judgments for assessing collectability and determining net revenues and accounts receivable from its customers. Management considers various historical collection factors for assessing collectability and determining net revenues and accounts receivable from our customers which include the period that the receivables have been outstanding, history of payment amounts, status of collections due, and applicable statutes of limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the nine months ended March 31, 2024 and 2023, healthcare insurers, government payers and OTC pharmaceutical sales accounted for over <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20230701__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HealthcareInsurersGovernmentPayersAndOTCPharmaceuticalSalesMember_z2lk8WtVPQbf" title="Concentrations risk, percentage">64</span>%, and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HealthcareInsurersGovernmentPayersAndOTCPharmaceuticalSalesMember_zytOEbjkV7Rj" title="Concentrations risk, percentage">28</span>% of total revenues, respectively. Also, healthcare insurers, government payers and OTC pharmaceutical sales amounted to total revenues of $<span id="xdx_909_eus-gaap--Revenues_pp0p0_c20230701__20240331__srt--ProductOrServiceAxis__custom--HealthcareInsurersGovernmentPayersAndOTCPharmaceuticalSalesMember_zpfZ2wPAXaZb" title="Revenues">14,012,544</span> and $<span id="xdx_905_eus-gaap--Revenues_pp0p0_c20220701__20230331__srt--ProductOrServiceAxis__custom--HealthcareInsurersGovernmentPayersAndOTCPharmaceuticalSalesMember_zBWHYwzHBxSg" title="Revenues">5,567,245</span> for the nine months ended March 31, 2024 and 2023, respectively. The accounts receivable related to both healthcare insurers and government payers is $<span id="xdx_906_eus-gaap--AccountsReceivableNet_iI_pp0p0_c20240331__srt--ProductOrServiceAxis__custom--HealthcareInsurersAndGovernmentPayersMember_zQLmOVunf9Fl" title="Accounts receivable">8,670,069</span> and $<span id="xdx_902_eus-gaap--AccountsReceivableNet_iI_pp0p0_c20230630__srt--ProductOrServiceAxis__custom--HealthcareInsurersAndGovernmentPayersMember_zDgDFJr04wdi" title="Accounts receivable">1,499,415</span> as of March 31, 2024 and June 30, 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of March 31, 2024 and June 30, 2023, $<span id="xdx_90A_eus-gaap--AccountsReceivableNet_iI_pp0p0_c20240331__srt--ProductOrServiceAxis__custom--LikidoUnitsMember_zY4YWz6WSl0l">612,803 </span>and $<span id="xdx_908_eus-gaap--AccountsReceivableNet_c20230630__srt--ProductOrServiceAxis__custom--LikidoUnitsMember_pp0p0">829,239 </span>is owed by customers from the sale of DCT One units, respectively.</p>
CY2024Q1	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	4691794	usd
CY2023Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	4285389	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	4870800	usd
CY2023	DFCO	Change In Fair Value Of Contingent Consideration1 ChangeInFairValueOfContingentConsideration1	-585411	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	4285389	usd
CY2023Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	4285389	usd
	DFCO	Change In Fair Value Of Contingent Consideration1 ChangeInFairValueOfContingentConsideration1	477072	usd
	DFCO	Contingent Consideration Common Stock Issuance ContingentConsiderationCommonStockIssuance	-70667	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	4691794	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	557401	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2430615	usd
CY2024Q1	us-gaap	Inventory Lifo Reserve InventoryLIFOReserve	0	usd
CY2024Q1	DFCO	Change In Fair Value Of Contingent Consideration1 ChangeInFairValueOfContingentConsideration1	289400	usd
	DFCO	Change In Fair Value Of Contingent Consideration1 ChangeInFairValueOfContingentConsideration1	477072	usd
CY2024Q1	DFCO	Contingent Consideration ContingentConsideration	4691794	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	433556	usd
CY2024Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10305791	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9474693	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21401633	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18985580	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	9841425	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	4453104	usd
CY2024Q1	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	909279	usd
CY2023Q2	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	752348	usd
CY2024Q1	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	20756	usd
CY2023Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	41722	usd
CY2024Q1	DFCO	Longterm Receivables Related Parties Current LongtermReceivablesRelatedPartiesCurrent	1146064	usd
CY2023Q2	DFCO	Longterm Receivables Related Parties Current LongtermReceivablesRelatedPartiesCurrent	1173893	usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue	471423	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	1337259	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5594338	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6612680	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13717562	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11924140	usd
CY2024Q1	us-gaap	Advertising Expense AdvertisingExpense	55265	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	75235	usd
	us-gaap	Advertising Expense AdvertisingExpense	144185	usd
	us-gaap	Advertising Expense AdvertisingExpense	275846	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1077390	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	815454	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3205859	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2184692	usd
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	426162	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zpjQofN48I08" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; font-size: 10pt"> </td> <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">(w)</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_866_zPDZInTIluA4">Reclassification</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">During the three months ended March 31, 2024, the company reclassified $3,851 of additional paid in capital to common stock par value and $604,000 from additional paid in capital and common stock par value to common stock to be issued. The reclassification had no impact on total operating costs, loss from operations, net loss, earnings per share or total equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p>
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	955568	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	658175	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1218522	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	708007	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	579118	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	712510	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	2753208	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2078692	usd
CY2024Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1603545	usd
CY2023Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1448556	usd
CY2024Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	409480	usd
CY2023Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	208689	usd
CY2024Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	470003	usd
CY2024Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	0	usd
CY2023Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	249613	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2483028	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2333020	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1057200	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	856938	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1425828	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1476082	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	323114	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	265749	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	170688	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	94331	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4350891	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4350891	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-492805	usd
	DFCO	Finite Lived Intangible Assets Accumulated Amortization Additions FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions	-297562	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-790367	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3560524	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	297562	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	264428	usd
CY2024Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	94299	usd
CY2023Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	87334	usd
CY2024Q1	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	637688	usd
CY2024Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0	usd
CY2023Q2	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	1900083	usd
CY2023Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	14182	usd
CY2024Q1	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	0	usd
CY2024Q1	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	637688	usd
CY2024Q1	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	637688	usd
CY2023Q2	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	251605	usd
CY2023Q2	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	1648478	usd
CY2023Q2	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	1900083	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	1733071	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	439562	usd
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	2281129	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	1011395	usd
CY2024Q1	us-gaap	Notes Payable NotesPayable	4014200	usd
CY2023Q2	us-gaap	Notes Payable NotesPayable	1450957	usd
CY2022Q1	DFCO	Redemption Premiums RedemptionPremiums	600000	usd
	DFCO	Payment Of Redemption Premium PaymentOfRedemptionPremium	0	usd
	DFCO	Payment Of Redemption Premium PaymentOfRedemptionPremium	120000	usd
	DFCO	Payment Of Redemption Premium In Stock PaymentOfRedemptionPremiumInStock	0	usd
	DFCO	Payment Of Redemption Premium In Stock PaymentOfRedemptionPremiumInStock	120000	usd
	DFCO	Accretion Interest Expense AccretionInterestExpense	0	usd
	DFCO	Accretion Interest Expense AccretionInterestExpense	180000	usd
	DFCO	Redeemed Cash RedeemedCash	0	usd
	DFCO	Redeemed Cash RedeemedCash	600000	usd
	DFCO	Redeemed Debentures RedeemedDebentures	0	usd
	DFCO	Redeemed Debentures RedeemedDebentures	300000	usd
CY2024Q1	DFCO	Revenue To Related Party RevenueToRelatedParty	524829	usd
CY2023Q1	DFCO	Revenue To Related Party RevenueToRelatedParty	183888	usd
	DFCO	Revenue To Related Party RevenueToRelatedParty	1639805	usd
	DFCO	Revenue To Related Party RevenueToRelatedParty	918648	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.45
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.59
CY2022Q1	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	1338644	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.45
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	250000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.15
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.08
CY2023Q2	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	2143402	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.10
CY2023Q2	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	47408	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.08
CY2023Q3	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	2064699	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12025000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M25D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	33426134	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.29
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	-0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	45451134	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.33
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M29D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	21566000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.14
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	9286111	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	57731023	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.26
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	34013575	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.32
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y29D
	us-gaap	Share Based Compensation ShareBasedCompensation	3205859	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2184692	usd
CY2024Q1	us-gaap	Revenues Revenues	10305791	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2289732	usd
CY2023Q1	us-gaap	Revenues Revenues	9474693	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3639220	usd
	us-gaap	Revenues Revenues	21401633	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11587202	usd
	us-gaap	Revenues Revenues	18985580	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11377487	usd
	us-gaap	Revenues Revenues	21401633	usd
	us-gaap	Revenues Revenues	18985580	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	2753208	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2078692	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1425828	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1476082	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	381517	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1438631	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1351056	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1232920	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	430907	usd
CY2024Q1	DFCO	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	32627	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4867658	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	414689	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4452969	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M6D
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M2D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0685	pure
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0674	pure
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
dfco-20240331_cal.xml	Edgar Link	unprocessable
0001683168-24-003323-index-headers.html	Edgar Link	pending
0001683168-24-003323-index.html	Edgar Link	pending
0001683168-24-003323.txt	Edgar Link	pending
0001683168-24-003323-xbrl.zip	Edgar Link	pending
dalrada_ex3101.htm	Edgar Link	pending
dalrada_ex3102.htm	Edgar Link	pending
dalrada_ex3201.htm	Edgar Link	pending
dalrada_ex3202.htm	Edgar Link	pending
dalrada_i10q-033124.htm	Edgar Link	pending
dfco-20240331.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
dfco-20240331_def.xml	Edgar Link	unprocessable
dfco-20240331_lab.xml	Edgar Link	unprocessable
dfco-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dalrada_i10q-033124_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DFCO
DALRADA FINANCIAL CORP Stock $dfco

2024 Q2 Form 10-Q Financial Statement

#000168316824003323 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFCO DALRADA FINANCIAL CORP Stock $dfco

2024 Q2 Form 10-Q Financial Statement

#000168316824003323 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFCO
DALRADA FINANCIAL CORP Stock $dfco